Floatz logo

Dat-2645

Ovarian Cancer

Danatlas Pharmaceuticals Co., LtdPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

524 Active assets in the Ovarian Cancer cohort.

Asset / SponsorPhaseRating
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
TIL
Inge Marie Svane
Phase 2BB
Olaparib
Shandong University
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
Kalinski, Pawel, MD, PhD
Phase 3BB
OTL-38
On Target Laboratories, LLC
Phase 4BB

View all 50 →

Same molecule, other indications

Dat-2645 is also rated in:

Solid CancersDormant
CC
Indicative ·
43 / 100
View asset →
HRD CancerDormant
CC
Indicative ·
43 / 100
View asset →
BRCA MutationDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →